Anti-inflammatory compounds and methods of use

Patent metadata

Field	Value
Publication number	US-10752662-B2
Application number	US-201815883999-A
Country	US
Kind code	B2
Filing date	Jan 30, 2018
Priority date	May 16, 2014
Publication date	Aug 25, 2020
Grant date	Aug 25, 2020

Abstract

Methods of treating or inhibiting inflammation in a subject include administering an anti-inflammatory protein to the subject. In some embodiments, the protein has at least 80% sequence identity to the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 17, or fragments thereof. Isolated polypeptides, nucleic acids, and recombinant vectors including a nucleic acid encoding the anti-inflammatory protein (such as a nucleic acid encoding a protein with at least 80% sequence identity to SEQ ID NO: 1, SEQ ID NO: 17, or fragments thereof) operably linked to a heterologous promoter are also disclosed.

First claim

We claim:

1. A method of treating inflammatory bowel disease, Hirschsprung's associated enterocolitis, irritable bowel syndrome, or necrotizing enterocolitis in a subject, comprising administering to the subject a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence 130-190 amino acids in length comprising amino acids 1-185 of SEQ ID NO: 1, amino acids 23-185 of SEQ ID NO: 1, or amino acids 192-313 of SEQ ID NO: 1.

2. The method of claim 1 , wherein the amount of the polypeptide administered to the subject is about 1 mg to about 5 g.

3. The method of claim 1 , wherein the polypeptide is administered to the subject daily, weekly, or monthly.

4. The method of claim 1 , further comprising administering one or more additional anti-inflammatory therapies to the subject.

5. The method of claim 1 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 1, amino acids 1-185 of SEQ ID NO: 1, amino acids 23-185 of SEQ ID NO: 1, or amino acids 192-313 of SEQ ID NO: 1.

6. The method of claim 1 , wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

Assignees

• Univ Oregon

Inventors

• Guillemin Karen
• Rolig Annah
• Sweeney Emily

Classifications

• A61P29/00 Primary

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• C07K4/12

  from animals; from humans · CPC title

• C07K14/4702 Primary

  Regulators; Modulating activity · CPC title

• C12N15/70

  Vectors or expression systems specially adapted for E. coli · CPC title